文献速递瓣膜病与结构性心脏病

TriClip三尖瓣缘对缘修复真实世界1年结果:bRIGHT研究

Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study.
PubMed 文献 · J Am Coll Cardiol · 2024-05-15

bRIGHT研究为前瞻性、单臂、开放标签、多中心上市后注册研究,纳入511例接受TriClip三尖瓣缘对缘修复的重度三尖瓣反流患者,1年时81%患者反流降至中度或以下,NYHA心功能分级和KCCQ评分显著改善;30天反流降至中度或以下者1年死亡率显著更低,基线肌酐和RV TAPSE与1年死亡率独立相关。

要点

  • TriClip三尖瓣TEER在真实世界重度TR患者中1年安全有效,81%反流降至中度或以下。
  • 30天反流降至中度或以下者1年死亡率显著更低,支持早期反流控制。
  • 基线肌酐升高和RV TAPSE降低与1年死亡率独立相关。

核心结论

  • TriClip三尖瓣TEER在重度三尖瓣反流且疾病晚期患者中1年安全有效,可显著改善心功能和生活质量。
  • 30天反流降至中度或以下与1年死亡率降低相关,但中度、轻度或微量反流之间死亡率无差异。

研究设计与样本

  • bRIGHT为前瞻性、单臂、开放标签、多中心上市后注册研究,在欧洲26个中心开展,设中心事件裁定和超声核心实验室评估。
  • 共纳入511例接受TriClip系统三尖瓣TEER的患者,年龄79±7岁,合并症显著,88%基线为大量或 torrential 三尖瓣反流,80%为NYHA III/IV级。

主要发现

  • 1年时81%患者三尖瓣反流降至中度或以下。
  • NYHA I/II级比例从21%升至75%(P<0.0001),KCCQ评分改善19±26分(P<0.0001)。
  • 30天反流降至中度或以下者1年死亡率显著更低,但30天中度、轻度或微量反流者间死亡率无差异。
  • 基线血清肌酐(OR: 2.169; 95%CI: 1.494-3.147; P<0.0001)和基线RV TAPSE(OR: 0.636; 95%CI: 0.415-0.974; P=0.0375)与1年死亡率独立相关。
  • 1年死亡率与基线三尖瓣反流分级或中心手术量无关。

临床怎么用

  • 对于重度三尖瓣反流且疾病晚期患者,TriClip三尖瓣TEER可作为改善反流、心功能和生活质量的治疗选择。
  • 术后早期(30天)实现反流降至中度或以下可能有助于降低1年死亡风险。
  • 基线肾功能和右心室功能(RV TAPSE)可用于风险分层。

局限性

  • 单臂、开放标签、非随机设计,无对照组,无法直接比较TEER与药物治疗或其他干预的疗效。
  • 研究人群为欧洲多中心选择性患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe tricuspid regurgitation (TR) is known to be associated with poor quality of life and increased risk of death when left untreated. OBJECTIVES: We sought to report the 1-year clinical outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair (TEER) with the TriClip system (Abbott Cardiovascular) in a contemporary real-world setting. METHODS: The bRIGHT (An Observational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip Device) postapproval study is a prospective, single-arm, open-label, multicenter postmarket registry conducted at 26 sites in Europe, with central event adjudication and echocardiographic core-laboratory assessment. RESULTS: Enrolled subjects (n = 511) were elderly (79 ± 7 years) with significant comorbidities. A total of 88% had baseline massive or torrential TR, and 80% of subjects were in NYHA functional class III/IV. TR was reduced to moderate or less in 81% at 1 year. Significant improvements in NYHA functional class (21% to 75% I/II, P < 0.0001) and Kansas City Cardiomyopathy Questionnaire (KCCQ) score (19 ± 26-point improvement, P <0.0001) were observed at 1 year. One-year mortality was significantly lower in subjects who achieved moderate or lower TR at 30 days; however, there was no difference in mortality among subjects who achieved moderate, mild, or trace TR at 30 days. In addition to TR reduction at 30 days, baseline serum creatinine and baseline right ventricular tricuspid annular plane systolic excursion (RV TAPSE) were independently associated with mortality at 1 year (OR: 2.169; 95% CI: 1.494-3.147; P < 0.0001; OR: 0.636; 95% CI: 0.415-0.974; P = 0.0375). Mortality was not associated with baseline TR grade or with center volume. CONCLUSIONS: Tricuspid TEER using the TriClip system was safe and effective through 1 year for subjects with significant TR and advanced disease in a diverse real-world population. (An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip Device [bRIGHT]; NCT04483089).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lurz P, Rommel KP, Schmitz T, et al. Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study. J Am Coll Cardiol. 2024. PMID: 38759905. doi:10.1016/j.jacc.2024.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。